CLAIMS:

1. A crystalline anhydrous N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, Form 1 having a ^{19}F solid state NMR spectrum comprising resonance values of -188.1 and -115.8 ppm ± 0.2 ppm .

2. The crystalline anhydrous N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, Form 1 according to claim 1, having a ^{13}C solid state NMR spectrum comprising resonance (ppm) values at 35.8, 57.5, 130.6 and 148.1 ppm ± 0.2 ppm.

3. The crystalline anhydrous N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, Form 1 according to claim 1 or 2, having a powder X-ray diffraction pattern measured using copper wavelength radiation comprising peaks, in terms of 2-theta, at 8.3, 11.5 and 16.1 degrees 2-theta ± 0.2 degrees 2-theta.

4. The crystalline anhydrous N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, Form 1 according to any one of claims 1 to 3, having a powder X-ray diffraction pattern measured using copper wavelength radiation comprising peaks, in terms of 2-theta, at 8.3, 11.5, 16.1, 22.9, and 23.6 degrees 2-theta (± 0.2 degrees 2-theta)

5. The crystalline anhydrous N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, Form 1 according to any one of claims 1 to 4, having a Raman spectrum comprising one or more wavenumber (cm^{-1}) values at 1308, 1433, 1447, 1548 and 1608 cm^{-1} ± 2 cm^{-1}.

6. A pharmaceutical composition comprising the crystalline anhydrous N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, Form 1 according to any one of claims 1 to 5, and one or more pharmaceutically acceptable excipients.

7. The pharmaceutical composition according to claim 6, further comprises microcrystalline cellulose, dibasic calcium phosphate anhydrous, crospovidone Type B and sodium stearyl fumarate.

8. Use of the crystalline anhydrous N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, Form 1 according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a BRAF-associated tumor.

9. The use of Claim 8, wherein said BRAF-associated tumor has a BRAF Class II mutation.

10. The use of Claim 8 or 9, wherein said BRAF-associated tumor is a cancer selected from lung cancer, melanoma, colorectal cancer, breast cancer, pancreatic cancer, thyroid cancer, prostate cancer, adenoid cystic carcinoma, appendiceal cancer, small intestine cancer, head and neck squamous cell carcinoma, angiosarcoma, bladder carcinoma, plasma cell neoplasm, hepato-pancreato-biliary carcinoma, ovary carcinoma, neuroendocrine cancer, cholangiocarcinoma and CNS cancers.

11. The use of Claim 8, wherein said BRAF-associated tumor has a BRAF Class I mutation.

12. The use of Claim 11, wherein said BRAF-associated tumor is selected from melanoma, colorectal cancer, thyroid cancer, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, and metastatic cancers thereof, and primary brain tumors.

13. The use of any one of Claims 8 to 12, wherein the medicament is to be conjointly administered with one or more additional anticancer agents.

14. The use of Claim 13, wherein the additional anticancer agent is a MEK inhibitor.

15. The use of Claim 14, wherein the MEK inhibitor is binimetinib or a pharmaceutically acceptable salt thereof.

16. The use of Claim 13, wherein the additional anticancer agent is an EGFR inhibitor, wherein the EGFR inhibitor is cetuximab.

17. The use of Claim 13, wherein the additional anticancer agents are a MEK inhibitor and an EGFR inhibitor, wherein the MEK inhibitor is binimetinib or a pharmaceutically acceptable salt thereof, and the EGFR inhibitor is cetuximab.

18. The crystalline anhydrous N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, Form 1 according to any one of claims 1 to 5, for use in therapy.